HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): Larry R. Kaiser Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Lambright, E. S. Articles by Kaiser, L. R. Search for Related Content PubMed PubMed Citation Articles by Lambright, E. S. Articles by Kaiser, L. R.

Ann Thorac Surg 2000;70:1865-1871
© 2000 The Society of Thoracic Surgeons

---

Original article: general thoracic

Efficacy of repeated adenoviral suicide gene therapy in a localized murine tumor model

^a Thoracic Oncology Research Laboratory, University of Pennsylvania Medical Center, Philadelphia, Pennsylvania, USA

Address reprint requests to Dr Kaiser, General Thoracic Surgery, 6 Silverstein Pavilion, Hospital of the University of Pennsylvania, 3400 Spruce St, Philadelphia, PA 19104
e-mail: kaiser{at}mail.med.upenn.edu

Presented at the Thirty-sixth Annual Meeting of The Society of Thoracic Surgeons, Fort Lauderdale, FL, Jan 31–Feb 2, 2000.

Background. Gene therapy using adenovirus to deliver herpes simplex virus thymidine kinase (Ad.HSVtk) followed by the administration of the prodrug ganciclovir has been an effective anticancer therapy in models of localized tumor (including malignant mesothelioma) and is currently being evaluated in clinical trials. To optimize this approach, we studied the effects of repeated injections of Ad.HSVtk in an animal model of localized tumor in both naive and immunized mice.

Methods. Immunocompetent animals with established abdominal tumor were treated with either one or three (given weekly) intraperitoneal injections of Ad.HSVtk (10⁹ plaque-forming units) followed by daily ganciclovir and monitored for survival. Survival studies were also performed in mice previously immunized with adenovirus.

Results. Animals treated with multiple courses of Ad.HSVtk showed significantly improved survival versus singly injected animals and control animals with some long-term survivors in the multiple injected group. Preexisting neutralizing immunity did not diminish this survival advantage.

Conclusions. Multiple treatments using an adenoviral vector to deliver HSVtk significantly improves survival in a murine intraperitoneal tumor model. The presence of preexisting neutralizing antibodies does not blunt this effect. Repeat Ad.HSVtk is a feasible approach and may be a useful strategy in human cancer gene therapy.

This article has been cited by other articles:

				R. Kurdow, A. S. Boehle, S. Haye, L. Boenicke, B. Schniewind, P. Dohrmann, and H. Kalthoff Ganciclovir prodrug therapy is effective in a murine xenotransplant model of human lung cancer Ann. Thorac. Surg., March 1, 2002; 73(3): 905 - 910. [Abstract] [Full Text] [PDF]

				P. J. Margetts, S. Gyorffy, M. Kolb, L. Yu, C. M. Hoff, C. J. Holmes, and J. Gauldie Antiangiogenic and Antifibrotic Gene Therapy in a Chronic Infusion Model of Peritoneal Dialysis in Rats J. Am. Soc. Nephrol., March 1, 2002; 13(3): 721 - 728. [Abstract] [Full Text] [PDF]